Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins (Q40696514)

22 September 2017

Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins (English)

1 reference

22 September 2017

4

David M Shaw

0 references

author name string

Kevin A Myers

1

1 reference

22 September 2017

Matthew G Ryan

2

1 reference

22 September 2017

Peter L Stern

3

1 reference

22 September 2017

David M Shaw

4

1 reference

22 September 2017

M Jim Embleton

5

1 reference

22 September 2017

Susan M Kingsman

6

1 reference

22 September 2017

Miles W Carroll

7

1 reference

22 September 2017

1 November 2002

1 reference

22 September 2017

1 reference

22 September 2017

9

1 reference

22 September 2017

11

1 reference

22 September 2017

884-896

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700513

22 September 2017

0 references

cites work

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

The macrophage - a novel system to deliver gene therapy to pathological hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

A 72 kD trophoblast glycoprotein defined by a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Isolation and characterization of 5T4, a tumour-associated antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Immunohistological distribution of 5T4 antigen in normal and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Investigation of expression of 5T4 antigen in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

The expression of 5T4 antigen in colorectal and gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

A transient three-plasmid expression system for the production of high titer retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

inferred from DOI database lookup

7 January 2021

based on heuristic

5T4 oncofetal antigen expression in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

inferred from DOI database lookup

7 January 2021

based on heuristic

Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700513

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700513

1 reference

Dimensions Publication ID

22 September 2017

0 references

1 reference